Abstract
Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.
Original language | English (US) |
---|---|
Pages (from-to) | 107-119 |
Number of pages | 13 |
Journal | Patient Preference and Adherence |
Volume | 11 |
DOIs | |
State | Published - 2017 |
Keywords
- Noncancer pain patients
- Opioid bowel disorder
- Opioid-associated side effects
- Opioid-induced constipation
- PAMORA
- Peripherally acting mu-opioid receptor antagonist
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Social Sciences (miscellaneous)
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Health Policy